NEW YORK, March 10, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Omega Protein Corporation (NYSE:OME) shares between June 4, 2013 and March 1, 2017 (the “Class Period”).
Investors who have incurred losses in Omega Protein Corporation shares are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased shares of Omega Protein Corporation within the class period and would like to assist with the litigation process, you may, no later than May 1, 2017, request that the Court appoint you lead plaintiff of the proposed class.
According to the filed complaint, in a series of filings with the U.S. Securities and Exchange Commission ("SEC"), Omega officials attested to the accuracy of the financial reporting, the disclosure of any material changes to the company's internal controls over financial reporting, and the disclosure of all fraud.
It is alleged that Omega officials failed to disclose that the SEC is requesting information in connection with its subsidiary, Omega Protein Inc. ("Omega Inc.") and that this could have a negative effect on Omega. On December 16, 2016, Omega filed a Form 8-K with the SEC announcing that Omega Inc. agreed to plead guilty to two felony counts under the Clean Water Act pursuant to a plea agreement with the United States Attorney's Office for the Western District of Louisiana.
On March 1, 2017, in its Form 10-K for the fiscal year ended December 31, 2016, Omega revealed that in December 2016, it "received a subpoena from the SEC requesting information in connection with an investigation relating to a Company subsidiary's compliance with its probation terms and the Company's protection of whistleblower employees." Omega further disclosed that this could result in a "material adverse effect on the Company's business, reputation, results of operation, and financial condition." On this news, Omega's stock fell $6.25 per share, or approximately 23.81%, from its previous closing price to close at $20.00 per share on March 2, 2017.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
Follow the firm and learn about newly filed cases on Twitter and Facebook.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774


SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 



